A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023.
Medicines in the same class as popular weight-loss therapies Ozempic and Wegovy may carry an increased risk of pancreatitis, intestinal blockage and stomach paralysis compared to an older obesity drug, Canadian researchers find.A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating Type 2 diabetes made by Novo Nordisk.
Nearly five in every 1,000 users of semaglutide drugs developed pancreatitis, compared to one of every 1,000 users of bupropion-naltrexone, the active ingredients in the weight-loss drug Contrave, according to a report in thePancreatitis, or inflammation of the pancreas, can cause severe abdominal pain.
Mahyar Etminan, an epidemiologist at the University of British Columbia and senior author of the study, said up to two per cent of patients who used semaglutide and liraglutide medications to lose weight developed gastrointestinal problems.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Novo Nordisk\u0027s Wegovy bonanza looms large in DenmarkExplore stories from Atlantic Canada.
Lire la suite »
Novo Nordisk\u0027s Wegovy bonanza looms large in DenmarkExplore stories from Atlantic Canada.
Lire la suite »
Ozempic linked to stomach paralysis, other gastrointestinal issues: UBC studyThe study, published in JAMA, found these adverse gastrointestinal effects happen in non-diabetic patients using the drugs specifically for weight loss.
Lire la suite »
Walmart says weight loss drugs are impacting food sales: ReportWalmart Inc. (WMT) is seeing customers on drugs like Ozempic putting a little less food in their carts. A Walmart executive says the retailer is seeing a 'slight change' in the carts of shoppers on the diabetes and weight loss drug Ozempic, Wegovy, and other appetite suppressants, according to a report from Bloomberg. Yahoo Finance Reporter Brooke DiPalma discusses the report and the potential impact of appetite suppressants on company margins. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Lire la suite »
Weight-Loss Drugs Like Ozempic Are Putting You at Higher Risk for Stomach Issues - BNN BloombergNovo Nordisk A/S drugs that are commonly used for weight loss were linked to a higher risk of bowel obstructions and other gastrointestinal side effects in patients with obesity than an older treatment.
Lire la suite »
Ozempic and similar drugs linked to gastrointestinal conditions, Canadian researchers findResearchers examined a random sample of health insurance claim records of 16 million patients in the U.S. between 2006 and 2020 for use of semaglutide drugs
Lire la suite »